Novavax | NVAX - Cost Of Sales


Novavax reported $60.62M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Adma Biologics USD 58.64M 3.88M Sep/2025
Agenus USD 137K 19K Mar/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
Cassava Sciences USD 3.96M 1.16M Sep/2025
Geron USD 1.31M 263K Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
MannKind USD 33.65M 13.44M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 452M 245M Dec/2025
Novartis USD 3.54B 216M Sep/2025
Novavax USD 60.62M 91.77M Sep/2024
Pfizer USD 6.29B 2.12B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
TG Therapeutics USD 38.14M 10.05M Dec/2025